Every material Form 8-K SpyGlass Pharma, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
SpyGlass Pharma announced interim 4-year results from its first-in-human trial of the Bimatoprost Drug Pad-IOL System, a cataract-surgery implant designed to lower eye pressure for glaucoma or ocular hypertension patients. The company reported a 37% mean reduction in intraocular pressure and no product-related adverse events among 21 evaluable patients, though the study is small and the product remains in clinical development with no approval yet.
Mean intraocular pressure fell 37%, from 25.1 to 15.9 mmHg, across all three dose groups at 4 years
86% of evaluable patients (18 of 21) remained off all topical IOP-lowering drops
No product-related adverse events were reported; the trial began with 23 patients, and 21 were evaluable at 48 months
Company plans to work with the FDA on a 505(b)(2) New Drug Application; long-term follow-up continues through 2029
SpyGlass Pharma closed its purchase of 100% of Advanced Vision Science, Inc. (AVS) on October 1, 2026, from Santen Holdings US, Inc. AVS had been SpyGlass Pharma's intraocular lens (IOL) supplier, and the company says the deal secures its IOL manufacturing supply for its Phase 3 BIM-IOL System.
Purchase price was $13,000,000, subject to customary adjustments, including a post-Closing adjustment
Closing occurred on October 1, 2026; Santen Pharmaceutical Co., Ltd. guaranteed the seller's obligations under the Purchase Agreement
AVS will continue to manufacture and supply Eternity brand IOLs to Santen, which has an exclusive right to sell them in Japan
AVS and Santen entered into cross license agreements allowing both parties to continue operating their businesses
SpyGlass Pharma reported its second quarter 2026 results, with a net loss of $19.9 million, or $0.59 per share, compared with $8.7 million, or $3.81 per share, a year earlier. Operating expenses rose as research and development and general and administrative costs increased, and the filing reports no revenue line. The company said its cash and short-term investments of $234.2 million are expected to fund planned operations through 2028.
Net loss was $19.9 million in Q2 2026, up from $8.7 million in Q2 2025; per-share loss was $0.59 versus $3.81, on a larger weighted share count of 33,439,543 versus 2,277,521.
Research and development expenses rose to $10.9 million from $7.3 million, mainly due to hiring clinical personnel.
General and administrative expenses rose to $11.0 million from $2.0 million, mainly due to higher professional service fees and personnel costs.
Cash, cash equivalents and short-term investments were $234.2 million on June 30, 2026, expected to fund operations through 2028.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every SpyGlass Pharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →